Impact of Covid-19 Pandemic on Patients Receiving Continuation or Maintenance Electroconvulsive Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

47 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-03-31

Study Completion Date

2020-06-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Electroconvulsive therapy is a safe and effective therapeutic strategy in patients with treatment resistant depression. As relapse after successful ECT is significant even with adequate pharmacological strategies, continuation (up to 6 months after completion of index-ECT) or maintenance ECT (more than 6 months after index-ECT) is often necessary to maintain remission. During the current Covid-19 pandemic hospitals redirected resources and closed or significantly diminished ECT services. In this study we aim to assess the impact of discontinuing maintenance electroconvulsive therapy in patients diagnosed with unipolar depressive disorder.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

RCT for Electroconvulsive Treatment Followed by Cognitive Control Training

NCT05683028

Depressive Episode Electroconvulsive Therapy Cognitive Remediation

COMPLETED NA

Efficacy of Electronic Cognitive Behavioral Therapy Application to Treat Major Depressive Disorder

NCT01752608

Major Depressive Disorder

WITHDRAWN NA

Efficacy of 18-Months of Antidepressive Medication Plus CBT or Dynamic or Supportive Psychotherapy for Recurrent Major Depression

NCT00220623

Major Depression

UNKNOWN PHASE3

Treatment of Post-covid Syndrome in Patients Treated in Intensive Care

NCT05119608

COVID-19 Mental Health Disorder

RECRUITING NA

Effects of Booster Sessions on Depression Vulnerability Following Cognitive Control Training

NCT05557760

Major Depression in Remission

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

During the height of the Covid-19 pandemic in Belgium all patients receiving continuation or maintenance electroconvulsive therapy (ECT) for major depressive disorder in two ECT centers in Belgium will be included. Due to differences in Covid-19 infection rates and hospital management decisions, one ECT-service temporarily halted all electroconvulsive treatments, where as the other ECT-service continued continuation and maintenance treatments. Depressive symptomatology and relapse rates will be assessed during the diminished accessibility of electroconvulsive treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Electroconvulsive Therapy Major Depressive Disorder Covid-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Discontinuation of C/M-ECT

Participants with major depressive disorder who are unable to continue maintenance (M-ECT) or continuation electroconvulsive therapy (C-ECT) due to hospital restrictions during Covid-19 or due to personal preference.

Questionnaires

Intervention Type OTHER

Participants will be contacted every three weeks to assess depressive symptomatology and possible relapse.

* Patient Health Questionnaire (PHQ-9)
* Clinical Global Impression (CGI)
* Scaling question regarding depressive symptomatology

Continuation of C/M-ECT

Participants with major depressive disorder who are able to continue maintenance (M-ECT) or continuation electroconvulsive therapy (C-ECT) during Covid-19.

Questionnaires

Intervention Type OTHER

Participants will be contacted every three weeks to assess depressive symptomatology and possible relapse.

* Patient Health Questionnaire (PHQ-9)
* Clinical Global Impression (CGI)
* Scaling question regarding depressive symptomatology

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Questionnaires

Participants will be contacted every three weeks to assess depressive symptomatology and possible relapse.

* Patient Health Questionnaire (PHQ-9)
* Clinical Global Impression (CGI)
* Scaling question regarding depressive symptomatology

Intervention Type OTHER